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OBJECTIVE—Adiponectin (APM1, ACDC) is an adipocyte-
derived protein with downregulated expression in obesity and
insulin-resistant states. Several potentially regulatory single nu-
cleotide polymorphisms (SNPs) within the APM1 gene promoter
region have been associated with circulating adiponectin levels.
None of them have been functionally characterized in adipo-
nectin-expressing cells. Hence, we investigated three SNPs
(rs16861194, rs17300539, and rs266729) for their inﬂuence on
adiponectin promoter activity and their association with circu-
lating adiponectin levels.
RESEARCH DESIGN AND METHODS—Basal and rosiglita-
zone-induced promoter activity of different SNP combinations
(haplotypes) was analyzed in 3T3-L1 adipocytes using luciferase
reporter gene assays and DNA binding studies comparing all
possible APM1 haplotypes. This functional approach was com-
plemented with analysis of epidemiological population-based
data of 1,692 participants of the MONICA/KORA S123 cohort and
696 participants from the KORA S4 cohort for SNP and haplotype
association with circulating adiponectin levels.
RESULTS—Major to minor allele replacements of the three
SNPs revealed signiﬁcant effects on promoter activity in lucif-
erase assays. Particularly, a minor variant in rs16861194 resulted
in reduced basal and rosiglitazone-induced promoter activity and
hypoadiponectinemia in the epidemiological datasets. The hap-
lotype with the minor allele in all three SNPs showed a complete
loss of promoter activity, and no subject carried this haplotype in
either of the epidemiological samples (combined P value for
statistically signiﬁcant difference from a random sample was
0.006).
CONCLUSIONS—Our results clearly demonstrate that pro-
moter variants associated with hypoadiponectinemia in humans
substantially affect adiponectin promoter activity in adipocytes.
Our combination of functional experiments with epidemiological
data overcomes the drawback of each approach alone. Diabetes
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dipose tissue produces and releases a variety of
factors, which may be directly involved in the
pathophysiology of obesity-associated insulin
resistance (1). One of the most interesting
candidates with respect to the development of metabolic
syndrome and type 2 diabetes is the APM1 gene that
encodes the abundantly expressed protein adiponectin.
Circulating adiponectin concentrations are negatively as-
sociated with insulin resistance and atherosclerosis and
are decreased in humans with type 2 diabetes, coronary
artery disease, or obesity (2). Animal experiments showed
that administration of adiponectin reduces blood glucose
levels, improves insulin resistance, and directly amelio-
rates endothelial dysfunction (3–5). Furthermore, low
adiponectin levels are associated with other components
of the metabolic syndrome, such as hypertension and
dyslipidemia (6).
APM1 maps to chromosome 3q27, a region known to be
linked to type 2 diabetes and the metabolic syndrome (7).
In view of the important role of circulating adiponectin in
the pathogenesis of major metabolic disorders, several
studies have addressed the correlation of APM1 SNPs with
adiponectin levels. They revealed a signiﬁcant correlation
between two SNPs, rs266729 and rs17300539, and adi-
ponectin levels (8–11). In one of these studies, the func-
tional activity of both SNPs for transcriptional regulation
as promoter elements was analyzed by luciferase assay
(11). However, these experiments were performed in
COS7 cells that do not express adiponectin and hence do
not represent an ideal cell system for this type of analysis.
We performed transfection experiments using mutated
promoter constructs in 3T3-L1 adipocytes expressing en-
dogenous adiponectin and analyzed DNA binding activity
of different haplotype combinations of three promoter
SNPs. Two of the selected SNPs are known to be associ-
ated with adiponectin levels and the third one lies in close
proximity. This prompted us to assume that all three may
be located in a transcriptionally functional element that
may be altered by one or all SNPs. The relevance of these
SNP haplotypes for human adiponectin levels was inves-
tigated in 1,692 participants of the MONICA/KORA (Coop-
erative Health Research in the Region of Augsburg) S123
cohort as well as in 696 participants of the KORA S4
cohort.
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SNP selection. We searched for SNPs in the promoter region of the APM1
gene that 1) co-localize with putative transcription factor binding sites, 2)
have been reported to be associated with adiponectin level or other adiponec-
tin-related traits, and 3) lie in close genomic proximity. The ﬁrst criterion is
based on the assumption that SNPs may interfere with the functionality of a
binding site, and the second should ensure previous epidemiological SNP
association with adiponectin or related parameters. The rationale for the third
criterion is the fact that transcription factor binding sites are often found in
close proximity and build a functional module; the combination of different
transcription factor binding sites is usually essential for regulation of tran-
scription. If potential regulatory SNPs are found in such a potential module, it
may enhance the probability that they are indeed functional SNPs. We
hypothesized that SNPs combining both properties were most likely to alter a
functional module in humans. The SNP2 (rs17300539, GA) showed the
strongest association with adiponectin levels in several studies (9–11). This
SNP has been chosen together with two additional SNPs that both have shown
association with type 2 diabetes (SNP1  rs16861194 AG; SNP3  rs266729
CG; in MONICA/KORA S123, rs1648707 AC has served as proxy for SNP3
with linkage disequilibrium values of r  0.84 and D1). All three together
are located in a small 80-bp part of the adiponectin promoter/enhancer region.
Furthermore, all three SNPs lie within putative transcription factor binding
sites that are shown in Fig. 1. These putative binding sites have been predicted
using the Genomatix software (Genomatix, Munich, Germany).
Functional studies
Cell culture. The mouse preadipocyte cell line 3T3-L1 was cultured as
described (12). To promote adipose differentiation, Dulbecco’s modiﬁed
Eagle’s medium containing 10% fetal calf serum was supplemented with 250
nmol/l dexamethasone and 0.5 mmol/l isobutyl-methylxanthine for the ﬁrst 3
days and 66 nmol/l insulin throughout the whole differentiation period.
Transfection of cells. 3T3-L1 cells were transfected on day 0, 6, and 8 of
differentiation, respectively, using the Lipofectamine 2000 transfection re-
agent (Invitrogen, Karlsruhe, Germany). A total of 2 g DNA and 2 l
transfection reagent were mixed according to the manufacturer’s instructions
and added to the cells for 4 h. Then 24–48 h after transfection, luciferase
activity was measured using the dual-luciferase reporter assay (Promega,
Mannheim, Germany). In all transfections, 0.2 g ubiquitin-promoter renilla
luciferase vector (12) was cotransfected to normalize for transfection
efﬁciency.
Cloning and mutagenesis of adiponectin promoter luciferase vectors. A
2,100-bp adiponectin promoter (bases 2,125 to 41) was PCR ampliﬁed from
genomic DNA using an iProof High-Fidelity PCR Kit (Bio-Rad, Germany) and
cloned into the pGL3basic luciferase vector (Promega, Germany) as described
recently (13), using the primers depicted in Table S1 in the supplemental
material (found in an online-only appendix at http://dx.doi.org/10.2337/db07-
1646). The haplotype conﬁguration of the cloned promoter was determined by
sequencing and was shown to carry the major allele (M) of the three SNPs
described above (MMM-luc). Using the QuickChange Multi Site-Directed
Mutagenesis Kit (Stratagene, Germany) and the primers listed in Table S1
(supplemental material), the variants of the three SNPs were introduced in all
remaining seven possible combinations (for primers, see Table S2). All vectors
were sequenced to conﬁrm the correct SNP variation combination.
Electrophoretic mobility shift assay. Probes for electrophoretic mobility
shift assay (EMSA) were ampliﬁed by PCR from the above-described lucif-
erase vectors carrying the eight different SNP combinations using the primers
EMSA 5 and 3 (Table S1). The resulting 80-bp probe spans the APM1 gene
corresponding to chromosome 3 position 188042104–188042183 (for se-
quence, see Figure S1 in the supplemental material). Primers contained a
synthetic HindIII site, and resulting probes were cut to enable radioactive
Klenow ﬁll-in. EMSA was performed with 2–4 g nuclear protein extract and
with 30,000–50,000 cpm of a
32P-labeled probe as described previously (14).
Statistical analysis of transfection studies. Overall, statically compari-
sons were performed using the Kruskal-Wallis test followed by pair-wise
testing using the Dunn’s multiple comparison test.
Epidemiological investigation
The KORA S4 and the MONICA/KORA S123 sample. The KORA Survey
S4 (formerly known as S2000) is a population-based study of adults recruited
from 1999 to 2001 conducted under the same conditions as the previous three
surveys (S1, S2, S3) with patients recruited during the years 1984–1995 in the
World Health Organization MONICA project. Details of the surveys are
reported elsewhere (15). Study participants from all four surveys were from
the study region of Augsburg (German nationality). Measures of weight and
height were available to compute the BMI. All participants gave their written
informed consent.
A subsample of the KORA S4 survey including 696 subjects aged 55–74
years with 50% men was designed to address objectives regarding pre-
diabetic stages. Adiponectin was measured in these subjects using the human
adiponectin radioimmunoassay from Linco Research (St. Charles, MO) as
described previously (16,17).
From the above-stated MONICA/KORA surveys S1, S2, and S3, a number of
the 1,692 subjects aged 35–74 years with equal gender distribution were
selected randomly from each survey as a subcohort sample (MONICA/KORA
S123 sample) (18). Adiponectin levels were measured using the human
adiponectin enzyme-linked immunosorbent assay from Mercodia (Uppsala,
Sweden). The intra- and interassay coefﬁcients of variation of control sera
were 3.2% and 5.8%, respectively.
Genotyping. PCR primers were designed by Sequenom’s MassARRAY Assay
Design program. Genotyping analyses were carried out by means of matrix-
assisted laser desorption ionization–time of ﬂight analysis of allele-dependent
primer extension products as described elsewhere (19). Genotyping calls
were made in real time with MassARRAY RT software (Sequenom, San Diego,
CA). Negative controls were included in all assays. In the 12.5% of randomly
selected samples genotyped in duplicate, the discordance rate was 0.3%.
Statistical analysis of epidemiological data. Statistical SNP and haplotype
association analysis was performed using the SAS procedure SURVEYREG to
account for the sampling scheme in the MONICA/KORA S123 sample in the
estimation of the standard errors of association estimates; in the KORA S4
sample, linear regression was applied using the GLM procedure. The loga-
rithm of adiponectin was used as the outcome variable to yield a normal
distribution. All analyses were adjusted for age, sex, and BMI. An additive as
well as a dominant genetic model was applied. The minor allele frequencies of
SNPs were computed, and linkage disequilibrium was assessed. SNPs were
tested for Hardy-Weinberg equilibrium.
Haplotypes were estimated from genotypes via the expectation-maximiza-
tion algorithm using the R statistics package (haplo.em) or SAS version 9.1
(20). Haplotypes were used in the regression models including all haplotypes
except the most common haplotype to compute the association with adi-
ponectin per copy of a haplotype adjusted for the other haplotypes compared
with the group of subjects with two copies of the most common haplotype.
RESULTS
SNP variants and haplotypes in the two epidemiolog-
ical KORA samples. In the two epidemiological cohorts
KORA S4 and MONICA/KORA S123, we analyzed the three
SNPs that we had selected for our investigation as candi-
dates for an adiponectin-regulating role because of their
nearby location in the APM1 promoter, because of their
possible interference to transcription factor binding sites,
and because of previous reports about association with
adiponectin or related phenotypes. The SNPs analyzed
were rs16861194 (SNP1), rs17300539 (SNP2), and rs266729
(SNP3) in KORA S4 and rs1648707 in MONICA/KORA S123
as proxy for SNP3 (as described in RESEARCH DESIGN AND
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FIG. 1. Schematic overview of the used promoter constructs. A: Sche-
matic overview of the luciferase reporter vectors used in this study
for transfections. Genomic location of the here analyzed SNP1
(rs16861194), SNP2 (rs17300539), and SNP3 (rs266729) are marked
(B). All experimentally veriﬁed transcription factor binding sites are
shown for the human (B) and mouse locus (C), and the here analyzed
SNPs are all located upstream of these sites. The genomatix-predicted
putative binding sites are depicted. SNP1 interferes with a putative
CART binding site and SNP2 with a putative NKXH binding site (both
sites for different families of homeobox proteins), and SNP3 interferes
with a zinc-ﬁnger binding site.
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2 values as a measure of linkage disequilib-
rium were 0.006 (0.009) and 0.024 (0.179) for SNP1 com-
pared with SNP2 and SNP3, respectively, and 0.038 (0.049)
for SNP2 compared with SNP3 in the KORA S4 sample
(and the MONICA/KORA S123 sample); hence, they are not
in linkage disequilibrium. We statistically reconstructed
the haplotypes; of the theoretically possible eight haplo-
types across the three SNPs, we observed ﬁve (MMM,
MmM, MMm, mMM, and mMm, with M and m indicating
the major or minor allele, respectively). SNP and haplo-
type characteristics are given in Tables 1 and 2, respec-
tively, indicating a large consistency of allele frequencies
in the two cohorts.
APM1 promoter activity during adipocyte differenti-
ation. The MMM adiponectin promoter construct contain-
ing the major allele M in all three SNPs was transfected
into 3T3-L1 preadipocyte cells (d0) and 3T3-L1 adipocytes
6 and 8 days after induction of differentiation (d6 and d8).
We measured a signiﬁcant induction of luciferase activity
during adipocyte differentiation (threefold on day 6 and
ﬁvefold on day 8, respectively) demonstrating the func-
tionality of the promoter (Fig. 2).
Next, we focused on the ﬁve haplotypes observed in the
KORA samples (MMM, MmM, MMm, mMM, and mMm). A
signiﬁcant overall difference between promoter activities
was observed (Fig. 2A), and each promoter construct
revealed signiﬁcant induction of luciferase activity upon
differentiation compared with respective transfections in
undifferentiated cells in pair-wise comparisons. On day 6
of differentiation, we found a tendency of 50% higher
promoter activity of the MMM promoter compared with
the mMM, MmM, and MMm promoters. On day 8 of
differentiation, the most striking difference was observed
between the MMM and the mMM promoter, with MMM
showing a threefold higher activity than mMM (P  0.05).
Notably, both promoters with the minor allele at the SNP1
position (mMM and mMm) revealed impaired basal pro-
moter activity compared with the MMM promoter already
in preadipocytes.
Next, we transfected cells with promoters regulated by
the theoretically possible, using nonexisting haplotypes in
the epidemiological samples (Mmm, mmM, and mmm),
and observed the strongest impact by the threefold major
to minor allele alteration (mmm promoter) with a com-
plete loss of basal promoter activity in preadipocytes.
Additionally, the mmm promoter was almost resistant to
transcriptional activation during differentiation supporting
the importance of these sites for transcription of the APM1
gene. Interestingly, all promoters with the minor allele at
the SNP1 position showed the strongest reduction of basal
promoter activity or altered kinetic of activity during
differentiation compared with the MMM promoter, sug-
gesting a crucial role of SNP1 for promoter activation.
TABLE 1
Characteristics of SNPs in the sample of the KORA S4 study (n  696) and the MONICA/KORA S123 study (n  1,692)
rs number Position* Call rate† (S4/S123)
Hardy-Weinberg equilibrium
P value‡ (S4/S123)
Minor allele frequency
(S4/S123)
SNP1 rs16861194 11426 0.966/0.988 0.494/0.865 0.059/0.083
SNP2 rs17300539 11391 0.951/0.990 0.347/0.897 0.091/0.090
SNP3§ Rs266729 11377 0.967/0.989 0.773/0.990 0.278/0.333
*Position relative to the ﬁrst position of the starting codon ATG; †proportion of genotyped sample, which successfully yielded a genotype;
‡testing for violation of HWE (exact); §rs266729 for KORA S4, the proxy rs1648707 for MONICA/KORA S123.
TABLE 2
Characteristics of haplotypes in the sample of the KORA S4 study
(n  696) and the MONICA/KORA S123 study (n  1,653*)
SNP1 SNP2 SNP3† Frequency (S4/S123)
MMM A G C 0.571/0.577
mMM G G C 0.059/0.0003
MmM A A C 0.091/0.090
MMm A G G 0.278/0.249
Mmm G A G 0/0
Mmm A A G 0/0
mMm G G G 0/0.083
mmM G A C 0/0
Haplotypes are given by stating m or M for each of the three SNPs in
a row indicating whether the haplotype exhibits the minor (m) or the
major (M) allele at the SNP location. *For complete data for all three
SNPs. †Depicted is the genotype CG of rs266729 measured in
KORA S4; the proxy rs1648707 with genotype AC (not depicted)
was measured in MONICA/KORA S123.
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FIG. 2. APM1 promoter activity during differentiation. Transient
transfection of 3T3-L1 cells at different stages of adipogenic differen-
tiation with the indicated APM1 promoter constructs is shown. A total
of 1 g of the indicated promoter construct (MMM  APM1 promoter
with the three described SNPs in the major conﬁguration, m  minor
variant, M  major variant) was transfected into 3T3-L1 cells at the
indicated day of differentiation (day 0  preadipocytes, day 6 and 8 
6 or 8 days after induction of differentiation). A total of 0.1 g
ubiquitin-renilla vector was cotransfected for normalization of the
transfection. The haplotypes observed in KORA samples are depicted
separately from the theoretically existing but not observed haplotypes.
Cells were harvested 24 h after transfection. Results are shown as the
ratio of ﬁreﬂy-/renilla-luciferase activity and the mean of minimal ﬁve
independent experiments  SD. The Kruskal-Wallis overall compari-
son of all constructs and observed/theoretical haplotypes is indicated
with P values; comparison of the day 0, 6, and 8 values for each
construct were P < 0.001 for MMM, P < 0.001 for MmM, P < 0.05 for
MMm, P < 0.001 for mMM, P < 0.001 for mmm, P < 0.005 for mmM, P
> 0.05 for Mmm, and P < 0.01 for mMm. The signiﬁcance of Dunn’s
multiple comparison test comparing the day 0 value for each construct
with its values at day 6 and day 8, respectively, is indicated with
asterisks: *P < 0.05 and **P < 001.
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ing on SNP variant combinations. To investigate
whether the different haplotype constructs had an impact
on the inducibility of the APM1 gene promoter, we trans-
fected 3T3-L1 adipocytes on day 6 after induction of
differentiation and determined luciferase activity in the
presence or absence of rosiglitazone. Promoters with
MMM, MmM, MMm, or Mmm haplotypes revealed a two- to
ﬁvefold induction of luciferase activity after treatment
with rosiglitazone compared with control treated cells
(Fig. 3). In contrast, all other haplotypes with the minor
variant at the SNP1 position (mMM, mMm, and mmm)
showed no response upon rosiglitazone treatment.
Inﬂuence of APM1 SNP variations on DNA binding
activity. To analyze whether these haplotypes have an
impact on DNA binding activity of nuclear proteins, we
performed EMSAs using nuclear extracts from undifferen-
tiated 3T3-L1 (preadipocytes) and in vitro differentiated
3T3-L1 adipocytes (day 6 after induction of differentiation)
and DNA probes with all eight possible haplotypes. We
found one major complex and some minor slower migrat-
ing complexes using the DNA probe with the major SNP
variants (MMM) and nuclear extracts from preadipocytes.
Nuclear extracts from differentiated adipocytes revealed a
slight decrease of the major complex and increased bind-
ing of a slower migrating complex. Most haplotypes
showed similar patterns of DNA binding compared with
MMM. In contrast, the mMM probe revealed strongly
reduced DNA binding activity with nuclear extracts from
preadipocytes, but comparable binding of major and mi-
nor complexes in differentiated adipocytes. Finally, we
performed EMSAs with nuclear extracts of preadipocytes
and adipocyte cultures that were induced with rosiglita-
zone to investigate whether stimulation affects DNA bind-
ing activity. Rosiglitazone treatment of preadipocytes
abolished protein binding to DNA probes with MMM and
the most other haplotypes (MmM, MMm, mmM, Mmm, and
mmm), whereas no inhibition of DNA binding was found
for the mMm variant. Moreover, we detected restored
DNA binding activity for the mMM variant. Surprisingly,
rosiglitazone treatment of differentiated adipocytes had no
major impact on DNA binding activity (Fig. 4).
Association of SNPs and haplotypes with circulating
adiponectin in the epidemiological samples. Tables 3
and 4 summarize the results of SNP and haplotype asso-
ciation analyses in the MONICA/KORA S123 (1,692 partic-
ipants) and the KORA S4 (696 participants) samples.
Subjects carrying the minor allele of SNP1 showed consis-
tently lower circulating adiponectin levels in both cohorts,
which was statistical signiﬁcant in the larger MONICA/
KORA S123 sample (P  0.001), but not in the smaller
KORA S4 sample. Consistent to the SNP1 ﬁnding, all
haplotypes found in the studies containing the minor allele
for SNP1 showed reduced adiponectin level, which was
statistically signiﬁcant for the more frequent mMm (P 
0.009). This observation of lower adiponectin level for the
SNP1 minor allele and the respective haplotypes is in line
with the promoter assay ﬁnding of a reduced activity for
these haplotypes. Subjects carrying the minor allele in
SNP2 showed a signiﬁcant increase in adiponectin levels
in both KORA samples (P  0.00005 and P  10
9), which
was in line with haplotype analysis for haplotype MmM
(P  0.0001 and P  0.0002), but did not ﬁt with the
promoter activity assays. SNP3 showed decreased adi-
ponectin levels in all studies, which was statistical signif-
icant in the larger MONICA/KORA S123 sample (P 
0.00001). Three haplotypes (mmM, Mmm, and mmm) were
neither present in any subject of the KORA S4 nor in the
MONICA/KORA S123 sample. Given the sample size of
1,676 (696) in the MONICA/KORA S123 (KORA S4) sample
and the haplotype frequency of 0.0025 (0.0015) as ex-
pected from the minor allele frequencies of the three
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FIG. 3. Inducibility of different haplotypes by rosiglitazone. Transient
transfection of 3T3-L1 cells with the indicated adiponectin promoter
constructs at day 6 after induction of differentiation is shown. A total
of 1 g of the indicated promoter construct was transfected into
3T3-L1 cells. A total of 0.1 g ubiquitin-renilla vector was cotrans-
fected for normalization of the transfection. The haplotypes observed
in MONICA/KORA S123 or S4 survey are separately depicted from the
theoretical existing, but was not observed in patients. At 24 h after
transfection, cells were induced with 1 mol/l rosiglitazone for 24 h as
indicated. Cells were harvested 24 h after transfection. Results are
shown as the ratio of ﬁreﬂy-/renilla-luciferase activity and the mean of
minimal three independent experiments  SD. Kruskal-Wallis overall
comparison of all constructs and of frequent/theoretical haplotypes is
indicated with a P value, followed by the Dunn’s multiple comparison
test comparing the uninduced () with the respective rosiglitazone-
induced () cells for each construct, as indicated with **P < 0.001.
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FIG. 4. DNA binding activity of different SNP variant combinations. An
80-bp fragment, described in RESEARCH DESIGN AND METHODS, was radio-
actively labeled, incubated with 2 g of the indicated protein extracts,
and separated on a gel as described. AC, 3T3-L1 adipocyte; PAC,
3T3-L1 preadipocyte; cells were induced with 1 mol/l rosiglitazone
() or with DMSO control ().
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type was statistically signiﬁcantly different from what
would have been expected by chance (P  0.0167 in
MONICA/KORA S123, P  0.3534 in KORA S4, P  0.0059
for both samples combined). This observation is in line
with the observation of a complete loss of promoter
activity.
DISCUSSION
Recent epidemiological studies support the concept that
SNPs in the APM1 gene are associated with type 2 diabetes
and other metabolic disorders in several populations (6).
In the current study, we investigated three different SNPs
(SNP1  rs16861194, SNP2  rs17300539, and SNP3 
rs266729 or rs1648707) in the APM1 gene promoter region
located within an 80-bp region of the promoter that are
known for their association with circulating adiponectin
levels or related phenotypes (9–11). We applied an ap-
proach of combining functional experiments with epide-
miological data and showed that these SNPs inﬂuence
basal and inducible APM1 promoter activity in 3T3-L1
adipocytes accompanied by alterations in DNA binding
activity. In human epidemiological studies, we presented
SNP and haplotype association analyses of two popula-
tion-based samples of the MONICA/KORA studies, which
was consistent with most of our functional ﬁndings.
Intriguingly, the constructed promoter with the minor
allele (mmm) in all SNPs was almost completely inactive
TABLE 3
SNP association analysis in the KORA S4 sample (n  696) and in the MONICA/KORA S123 sample (n  1,692)
SNP Genotype n Mean* (g/ml) Coefﬁcient (P)
Additive† Dominant‡
S123 (n  1,692) AA 1407 11.2062 Reference Reference
SNP1 AG 253 10.5341 0.0602 (P  0.0014) 0.0634 (P  0.002)
GG 12 10.1812
GG 1388 10.7692 Reference Reference
SNP2 AG 274 12.7478 0.1665 (P  10
9) 0.1748 (P  10
9)
AA 13 14.6926
AA 745 11.4570 Reference Reference
SNP3
§ CA 743 10.8979 0.0502 (P  0.00001) 0.0598 (P  0.0001)
CC 185 10.3596
S4 (n  696) AA 596 8.929 Reference Reference
SNP1 AG 73 8.536 0.0362 (P  0.507) 0.0248 (P  0.6677)
GG 3 4.967
GG 544 8.536 Reference Reference
SNP2 AG 115 10.164 0.1897 (P  0.00005) 0.2042 (P  0.00003)
AA 3 9.7
CC 349 9 Reference Reference
SNP3
§ GC 274 8.876 0.0287 (P  0.3273) 0.0185 (P  0.6167)
GG 50 8.422
Data are from linear regression on log(adiponectin), adjusted for age, sex, and BMI and survey (for the S123 sample) using an additive or
a dominant genetic model. *Geometric mean of adiponectin concentrations in micrograms adiponectin per milliliter serum. †Mean change
in log(adiponectin) per copy of the minor allele. ‡Mean change in log(adiponectin) for subjects to the indicated reference (e.g., SNP1 with
the AG or GG compared with the AA). §For SNP3 in the case of KORA S4, the genotype CG of rs266729 is depicted; in the case of
MONICA/KORA S123, the genotype AC of the proxy rs1648707 is depicted.
TABLE 4
Haplotype association analysis in the KORA S4 sample (n  696) and the MONICA/KORA S123 sample (n  1,653*)
Haplotype n Geometric mean† Coefﬁcient
S123 (n  1,676) MMM 0/1/2 300/799/554 11.343/11.035/11.029 Reference
MmM 0/1/2 1,368/272/13 10.761/12.738/14.683 0.15641 (P  0.0001)
MMm 0/1/2 927/628/98 11.298/10.832/10.792 0.022 (P  0.1009)
mMM 0/1/2 NA NA NA
mMm 0/1/2 1389/252/12 11.203/10.520/10.174 0.0489 (P  0.0091)
S4 (n  696) MMM 0/1/2 119/356/221 9.003/8.878/8.758 Reference
MmM 0/1/2 578/115/3 8.597/10.164/9.7 0.1775 (P  0.0002)
MMm 0/1/2 352/294/50 8.993/8.777/8.422 0.0155 (P  0.603879)
mMM 0/1/2 620/73/3 8.918/8.536/4.967 0.019 (P  0.733164)
mMm 0/1/2 NA NA NA
Results from linear regression models on log(adiponectin), adjusted for age, sex, and BMI, survey (for the S123 sample), and the other
haplotypes, with MMM being the reference using an additive genetic model. Haplotypes are depicted by m and M for the minor or major allele,
respectively, in SNP1, SNP2, and SNP3. 0/1/2  number of reconstructed haplotype copies. *For complete data for all three SNPs. †Geometric
mean of adiponectin concentrations (g/ml) per copy of the reconstructed haplotypes.
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tazone-induced activity. Our results clearly demonstrate
the functional relevance of these SNPs for activation of the
APM1 promoter by interfering with transcription factor
binding sites. Indeed, we found speciﬁc binding of nuclear
proteins to a DNA probe containing all three minor alleles
as well as changes in the pattern of DNA-protein com-
plexes upon adipocyte differentiation and partly also upon
rosiglitazone stimulation. Given the highly reduced pro-
moter activity and low circulating adiponectin levels being
associated with increased risk of severe diseases such as
type 2 diabetes and coronary heart disease (3,4,21–27),
one may speculate that the mmm haplotype affects adi-
ponectin expression in vivo to an extent that might be
disadvantageous. This hypothesis is supported by our
epidemiological ﬁnding that none of the 2,340 subjects in
our analysis carried this haplotype, which was highly
signiﬁcantly different from what would have been ex-
pected by chance (P  0.0059). Yet, further studies in
humans are necessary to support this hypothesis. The
importance of haplotype combination has also been
shown for SNP2 and SNP3, which in combination, in-
creases the risk of diabetes (28).
The transcription factors involved in the regulation of
the APM1 promoter were analyzed by several groups
(29–31); however, most studied promoter regions do not
contain the SNPs analyzed here. One study demonstrated
slightly higher promoter activity upon deletion of the
promoter region containing these SNPs (13). However,
such deletion of promoter regions removes all regulatory
sites and hence does not allow a SNP-speciﬁc analysis
concerning the inﬂuence on binding characteristics of
transcriptional activators or repressors. Indeed, our EMSA
experiments revealed the existence of speciﬁc DNA bind-
ing complexes that are affected by adipocyte differentia-
tion and rosiglitazone stimulation. At least two minor
alleles in the haplotype (mMM or mMm) exhibited obvious
alterations in DNA binding complexes. Surprisingly, the
presence of relevant DNA binding factors was already
found in preadipocytes. It has to be considered that
epigenetic mechanisms may also be involved in the regu-
lation of the analyzed promoter. It is known that transcrip-
tion of the APM1 gene is regulated by histone acetylation
(32). Interestingly, DNA binding activity upon rosiglita-
zone stimulation critically depends on the combination of
several SNP variants. This supports the view that this
promoter region represents a functional module with
binding of various proteins that interact and build a more
complex structure. As an example, we found alterations in
DNA binding activity using the DNA probe with the minor
SNP1 allele and nuclear extracts from preadipocytes.
Further introduction of a minor allele in SNP2 restored
normal DNA binding, whereas introduction of a minor
allele in SNP3 resulted in a different pattern of DNA
binding activity.
A potential limitation of our study is that mouse 3T3L1
cells may differ from human adipocytes regarding the
presence of transcription factors. However, several tran-
scription factors such as C/EBPs, SREBP, and PPARs were
previously shown to regulate both the human and mouse
adiponectin promoter, and the binding sites were well
characterized (29–31) (Fig. 1). Bioinformatics binding site
prediction revealed putative binding sites for the large
family of homeodomain proteins and zinc ﬁnger proteins,
yet clearly no binding sites for the so far known regulators
of adiponectin. Although we could clearly show that the
SNPs modulate DNA binding activity, the exact binding
factors remain to be identiﬁed. A recent publication also
suggested SNP3 by bioinformatics prediction to modify a
zinc ﬁnger protein site (33), but in this work, no attempt
was made to analyze the inﬂuence of the SNP3 on DNA
binding activity.
The correlation between elevated circulating adiponec-
tin levels and the presence of the minor allele in SNP2 is in
line with published data and with a recent report of
increased promoter activity in COS-7 cells (11). However,
COS-7 is not an adipocyte cell line and may not express an
appropriate set of transcription factors expected in adipo-
cytes. Direct adiponectin measurement of endogenous
adiponectin is not possible in the available cell models,
since the cell line does not contain the different genomic
haplotypes, but our transfection studies represent a good
model to address this aspect.
The minor allele of SNP2 resulted in a higher inducibility
by rosiglitazone only in the combination with the major
allele in SNP1. Even more for some minor allele con-
structs, this inducibility was increased from a lower basal
level, whereas the haplotype with three minor alleles was
not inducible at all. This serves as an additional hint for a
functional interaction between these two SNPs and fur-
thermore that a functional analysis of SNPs should also
take into account the activation state of cells. Peroxisome
proliferator–activated receptor (PPAR)-	 agonists such as
rosiglitazone are known to induce adiponectin expression
in adipocytes (34,35). Furthermore, treatment of type 2
diabetic patients with rosiglitazone improves insulin sen-
sitivity but stimulates fat accumulation (36). The response
to glitazones in humans could possibly differ depending on
the promoter haplotype, which pinpoint a potential rele-
vance of the APM1 promoter SNPs for improved individ-
ualized treatment.
We found obvious changes in the promoter and DNA
binding activity when the minor allele in SNP1 was
present. These ﬁndings are in line with the known associ-
ation of SNP1 with hypoadiponectinemia (9–11) and the
signiﬁcantly lower adiponectin levels in our MONICA/
KORA S123 sample. Moreover, the epidemiological haplo-
type data extend these ﬁndings, with adiponectin being
downregulated by the minor allele of SNP1 and upregu-
lated by the minor allele of SNP2. An important challenge
for the future characterization of this functional module is
the identiﬁcation of the nuclear factors whose binding is
affected by SNP1 and SNP2.
We used a combined functional and epidemiological
approach and thus were able to overcome the drawback of
each approach separately: On the one side, in epidemio-
logical studies, it is not clear whether a signiﬁcant SNP
association is derived from the analyzed SNP directly or
from a latent SNP in linkage disequilibrium. Signiﬁcant
haplotype associations can pinpoint a certain haplotype of
interest, but it would remain to be shown which speciﬁc
allele combination—and possibly including latent alleles
between genotyped loci—would be of functional rele-
vance. This is overcome by our functional haplotype
promoter studies where all effects are clearly attributed to
the distinct alterations analyzed, since polymorphisms in
linkage disequilibrium have not been mutated; hence a
major functional impact is exerted by the combination of
the here analyzed SNPs. On the other hand, functional
studies alone do not allow the drawback to effects in
humans. This limitation is overcome by adding epidemio-
logical data, which support the functional ﬁndings regard-
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haplotype combination, and a potential negative selection
of the haplotype with minor alleles in all three SNPs due to
suppressed adiponectin promoter activity.
In conclusion, the present study on the APM1 gene is the
ﬁrst one analyzing the functional activity of APM1 regula-
tory SNPs in a cell model expressing endogenous adi-
ponectin and shows the importance to consider SNP
haplotypes. The epidemiological data support the func-
tional ﬁndings and thereby underscore the relevance in
humans. Our results demonstrate that promoter variants
in the APM1 gene are relevant for the regulation of
adiponectin transcription. Furthermore, our study repre-
sents a suitable approach by combining functional and
epidemiological methods to characterize the role of gene
variants.
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